Document 0109
 DOCN  M95B0109
 TI    Correlation of clinical progression in human immunodeficiency
       virus-infected children with in vitro zidovudine resistance measured by
       a direct quantitative peripheral blood lymphocyte assay.
 DT    9511
 AU    Nielsen K; Wei LS; Sim MS; Deveikis A; Keller M; Stiehm ER; Frenkel LM;
       Bryson YJ; Department of Pediatrics, UCLA Medical Center 90024-1752,
       USA.
 SO    J Infect Dis. 1995 Aug;172(2):359-64. Unique Identifier : AIDSLINE
       MED/95348532
 AB    A rapid method for determination of zidovudine resistance was developed
       and results were correlated with clinical outcome in human
       immunodeficiency virus (HIV)-infected children. The zidovudine
       susceptibilities of HIV-1 isolates from 34 children were determined
       through a direct quantitative peripheral blood lymphocyte assay and
       compared with results of the AIDS Clinical Trials Group resistance
       assay. Patients' peripheral blood lymphocytes were 5-fold diluted and
       cocultured with donor lymphocytes and varying concentrations of
       zidovudine. Isolates were defined as sensitive if inhibited by < or =
       1.0 microM zidovudine and resistant at > 1.0 microM. Children (n = 21)
       with zidovudine-resistant virus had greater evidence of disease
       progression than did those with zidovudine-sensitive virus (n = 11) as
       demonstrated by failure to thrive (57% vs. 9%, P = .01) and
       opportunistic infections (48% vs. 0, P = .006). This assay may be useful
       as a screening tool for development of clinically relevant zidovudine
       resistance.
 DE    Child  Child, Preschool  Comparative Study  Disease Progression  Drug
       Resistance, Microbial  Follow-Up Studies  Human  HIV/DRUG EFFECTS  HIV
       Core Protein p24/BLOOD  HIV Infections/BLOOD/*DRUG THERAPY/VIROLOGY
       Infant  Lymphocytes/DRUG EFFECTS  Microbial Sensitivity Tests/*METHODS
       Support, Non-U.S. Gov't  Support, U.S. Gov't, P.H.S.
       Zidovudine/PHARMACOLOGY/*THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).